The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
- 31 March 2009
- journal article
- Published by Elsevier BV in Microvascular Research
- Vol. 77 (2), 78-86
- https://doi.org/10.1016/j.mvr.2008.08.003
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and ProgressionCancer Research, 2007
- Preconditioning of the Tumor Vasculature and Tumor Cells by Intermittent Hypoxia: Implications for Anticancer TherapiesCancer Research, 2006
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- Current methods for assaying angiogenesisin vitroandin vivoInternational Journal of Experimental Pathology, 2004
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- The Hallmarks of CancerCell, 2000
- Is angiogenesis inhibition the Holy Grail of cancer therapy?Current Opinion in Oncology, 2000
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994